CA2605112C - Solid transdermal therapeutic system comprising uv absorber - Google Patents

Solid transdermal therapeutic system comprising uv absorber Download PDF

Info

Publication number
CA2605112C
CA2605112C CA2605112A CA2605112A CA2605112C CA 2605112 C CA2605112 C CA 2605112C CA 2605112 A CA2605112 A CA 2605112A CA 2605112 A CA2605112 A CA 2605112A CA 2605112 C CA2605112 C CA 2605112C
Authority
CA
Canada
Prior art keywords
transdermal therapeutic
therapeutic system
solid transdermal
absorber
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2605112A
Other languages
French (fr)
Other versions
CA2605112A1 (en
Inventor
Thomas Langguth
Stefan Bracht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luye Pharma Switzerland AG
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CA2605112A1 publication Critical patent/CA2605112A1/en
Application granted granted Critical
Publication of CA2605112C publication Critical patent/CA2605112C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a novel solid transdermal therapeutic system with UV absorber which is particularly designed for photosensitive active pharmaceutical ingredients. The UV-stable transdermal therapeutic system (TTS) consists of a backing layer 1, of at least one active ingredient-containing matrix 2 and of a detachable protective film 3, it optionally being for an adhesive layer 4 and a separating layer 5 to be introduced between the backing layer 1 and the active ingredient-containing matrix 2. UV absorbers from the group of hydroxyphenyltriazines can be embedded in the backing layer 1 or in the active ingredient-containing matrix 2 or in the adhesive layer 4.
The TTS according to the invention achieves high stability with a low concentration of UV absorber. It is thus possible in particular to avoid or reduce the risk of possible skin irritation.

Description

Solid transdermal therapeutic system comprising UV
absorber (Description) Technical Field The invention relates to a solid transdermal therapeutic system with UV absorber. The UV-stable transdermal therapeutic system (TTS) is particularly designed for photosensitive active pharmaceutical ingredients.
The transdermal therapeutic system according to the invention, if appropriate comprising a progestrogen and/or an estrogen, is also suitable for fertility control.
Prior Art Attempts. to employ photosensitive active ingredients which absorb UV-A and UV-B rays normally in sun creams ,are known, as described by Briscart & Plaizier-Vercammen (Proc. 2nd World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, APGI/APV, 1998, 1231-1232).
The patent literature further discloses the protection of transdermal therapeutic systems (TTS) provided with photosensitive active ingredients by means of visually conspicuous aluminized or lacquered covering films as backing layer of the TTS.
WO-Al-00/56289 describes a method for protecting therapeutic preparations, systems or their constituents, the intention being to achieve in each case specific protection from degradation by harmful factors such as atmospheric oxygen, water and/or light.
Photoprotective substances which absorb or reflect electromagnetic waves are used, employing respectively absorbents or reflectants whose absorption or reflection spectrum covers the wavelength range
- 2 -responsible for the instability of the photosensitive substance or its constituents. Coloured plastic films are used inter alia in this case as covering film, indicated by example of the 1,4-dihydropyridine derivative lacidipine.
The colouring of highly flexible plastic films proves to be difficult and does not provide reliable photoprotection owing to the frequently occurring fissures in the coloured layer of the plastic film.
WO-A2-02/34200 further discloses transdermal therapeutic systems (TTS) which consist of an active ingredient-containing polymer matrix and of a backing layer, where polymer matrix and backing layer are firmly connected or form a laminate, and both the polymer matrix and the backing layer comprise a colourless system which absorbs in the UV range but has no intrinsic pharmacological effect.
EP-A1-1452173 indicates transdermai therapeutic ,systems which consist of a backing layer, of at least one .active ingredient-containing matrix and optionally of a Kletachable:film and comprises a Tri= absorber, whereat :least one UV, absorber-containing adhesive layer is . provided between the backing layer and the active ingredient-containing matrix which is furthest away from the surface of the skin, and at least one separating layer which is impermeable to active ingredient and impermeable to the UV absorber is present between the adhesive layer containing the UV
absorber and the active ingredient-containing matrix which is furthest away from the surface of the skin. It is possible in this case to select as UV absorbers the UV absorbers from the group of p-aminobenzoic acid, aminobenzoic acid derivative, preferably 2-ethylhexyl 4-dimethylaminobenzoate and/or polyethoxyethyl 4-bis(polyethoxy)aminobenzoate, cinnamic acid, cinnamic acid derivatives, preferably isoamyl 4-methoxycinnamate and/or 2-ethylhexyl 4-methoxycinnamate,
3-benzylidenebornan-2-one, benzylidenebornan72-pne derivatives, preferably 3-(4')-methylhenzylidenebornan-2-one, 3-(4-sulphone)benzylidenebornan-2-one and/or 3-(4'-trimethylammonium)benzylidenebornan-2-one methyl-sulphate, salicylic acid derivative, preferably 4-iso-propylbenzyl salicylate, 2-ethylhexyl salicylate, and/or 3,3,5-trimethylcyclohexyl salicylate, benzo-triazoles, preferably 2-(5-chloro-2H-benzotriazol-2-y1)-6-(1,1-dimethylethyl)-4-methylphenol, 2,4,6'-tri-aniline-p-(carbo-2'-ethylhexyl-l'-oxy)-1,3,5-triazine, 3-imidazol-4-ylacrylic acid, 3-imidazol-4-y1-3-imidazol-4-ylacrylic ester, 2-phenylenebenzimidazole-5-sulphonic acid and/or their K, Na and triethanolamine (=TEA) salts, 2-cyano-3,3-diphenylacrylic acid, terephthaloylidenedicamphorsulphonic acid, butyl-methoxydibenzoylmethane, benzophenone and/or benzo-phenone derivatives, preferably benzophenone-3 and/or benzophenone-4.
The known solutions have the disadvantage - that the protective effect produced by the added UV absorber for the active ingredient is incomplete, - that owing to the incomplete protective effect in some cases higher concentrations of UV absorbers must be employed, which may have adverse effects on the compatibility of the TTS with skin.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a graphical illustration showing the percentage of photosensitive active ingredient remaining in a transdermal therapeutic system according to the invention with photo-protective features and the percentage of photosensitive active ingredient remaining in a comparative transdermal therapeutic system; and Figures 2 to 4 are respective diagrammatic cross-sectional views through various embodiments of the - 3a -transdermal therapeutic systems according to the invention.
Summary of the invention It is therefore an object of the invention to provide a pharmaceutical preparation which is provided with a photosensitive active ingredient and is to be administered transdermally, and which ensures an increased protective effect for the active ingredient on use of a minimal UV absorber concentration which avoids the aforementioned disadvantages.
The object is achieved according to the invention by a solid transdermal therapeutic system with UV absorber.
- 4 -The UV-stable TTS consists in its sequence of layers in this case of a backing layer 1, of at least one active ingredient-containing matrix 2 and of a detachable protective film 3, it optionally being for an adhesive layer 4 and a separating layer 5 to be introduced between the backing layer 1 and the active ingredient-containing matrix 2. UV absorbers from the group of hydroxyphenyltriazines can be embedded in the backing layer 1 or in the active ingredient-containing matrix 2 or in the adhesive layer 4.
It is possible according to the invention for the UV
absorber to be 2,4-bis-[4-(2-ethylhexyloxy)-2-hydroxy]pheny1-6-(4-methoxypheny1)-(1,3,5)-triazine.
It is furthermore possible according to the invention for the weight per unit area of the matrix 2 to be from 30 to 150 g/m2. In this connection, a weight per unit area of from 50 to 120 g/m2 is preferred, and of 100 g/m2 is particularly preferred.
It is also possible in the solid transdermal therapeutic system according to the invention for the weight per unit area of the adhesive layer 4 to be from
5 to 50 g/m2. In this connection, a weight per unit area of from 20 to 30 g/m2 is preferred.
The UV absorber can be present according to the invention in the adhesive layer 4 in the concentration of from 0.5 to 5% (m/m) in dissolved form. In this connection, a concentration of from 1.0 to 4.0% is preferred, and of from 1.5 to 3.0% is particularly preferred.
The matrix 2 and/or the adhesive layer 4 in the solid transdermal therapeutic system can furthermore be designed according to the invention to be self-adhesive and to consist substantially of polymers which are selected from the groups = of polyisobutylene, polybutene, polyacrylate, polydimethylsiloxane, styrene-isoprene block polymer or polyisoprene.
It is also possible in the solid transdermal therapeutic system according to the invention for the separating layer 5 to have a layer thickness of from 4 to 23 pm. In this connection, the layer thickness of from 4 to 10 pm is preferred.
It is possible according to the invention in the solid transdermal therapeutic system for separating layer 5 to be impermeable to active ingredient and impermeable to the UV absorber.
It is furthermore possible according to the invention for the separating layer 5 in the solid transdermal therapeutic system to consist of a barrier polymer.
Preference is given in this connection to polyethylene terephthalate or polyacrylonitrile or polyvinyl_ chloride or polyvinylidene chloride or its copolymers or colaminates.
It is also possible in the solid transdermai therapeutic system according to the invention for the backing layer 1 to be permeable to active ingredient and to consist of polypropylene, polyethylene, polyurethane, ethylene-vinyl acetate copolymer or of a multilayer composite of these materials with one another or with other materials.
The UV absorber(s) in the solid transdermal therapeutic system may according to the invention be colourless or yellowish.
It is furthermore possible for the solid transdermal therapeutic system according to the invention to be transparent or slightly opaque.
It is also possible for at least one hormone to be
- 6 -active as active ingredient in the solid transdermal therapeutic system according to the invention.
It is possible according to the invention for the active pharmaceutical ingredients to be a progestogen.
Preference is given in this case to gestodene or levonorgestrol.
It is furthermore possible to add an estrogen to the progestogen in the solid transdermal therapeutic system according to the invention. Preference is given in this case to ethynylestradiol.
It is also possible according to the invention for the solid transdermal therapeutic system to be used in fertility control.
It is further possible according to the invention to use one. or, more UV absorbers from the group of . the hydroxyphenyltriazines for producing a solid trandermal system, whose sequence of layers consists of at least three layers, this sequence of layers starting furthest =
away from the skin with a backing layer 1, an at least monolayer active ingredient-containing matrix 2, a detachable protective film 3 and optionally, introduced between backing layer 1 and active ingredient-containing matrix 2, an adhesive layer 4 and separating layer 5 following the active ingredient-containing matrix 2 for fertility control, and where the UV
absorber(s) from the group of hydroxyphenyltriazines is/are embedded in the backing layer 1 or in the active ingredient-containing matrix 2 or in the adhesive layer 4.
It is also possible according to the invention for the solid transdermal therapeutic system to be equipped without a membrane controlling active ingredient release.
- 7 -The transdermal therapeutic system according to the invention has the following advantages compared with conventional systems with photosensitive active ingredient content:
- The protective effect provided by the UV absorber from the group of hydroxyphenyltriazines is enhanced and - the concentration of the UV absorber from the group of hydroxyphenyltriazines which is necessary to achieve a protective effect is reduced.
- It is =thus possible in particular to avoid or reduce the risk of possible skin irritation.
Exemplary embodiments The invention is explained further by the following examples.
Example 1 Two formulations of a photosensitive active ingredient from the group of progestogens= wera prepared.
Formulation 2 comprises an adhesive layer and a separating layer, and the adhesive layer comprises 2.5%
by weight of a UV-absorbing substance from the class of the hydroxyphenyltriazines.
Formulation 1 comprises no adhesive layer and separating layer and serves as comparative formulation.
Both formulations comprise an active ingredient-containing matrix with a photosensitive progestogen and are equipped with a backing layer of polyethylene, resulting in a TTS in each case.
Formulation 2 has the following composition:
1. Active ingredient-containing matrix:
- 1.9% progestogen - 98.1% polyisobutylene-based adhesive 2. Adhesive layer:
- 2.5% Tinosorb S
- 97.2% polyisobutylene-based adhesive
- 8 -Tinosorb S (from Ciba, Lampertheim) is a UV absorber of the hydroxyphenyltriazine class.
To investigate the photoprotective effect, both formulations were irradiated with light having a UV
spectrum of 300-800 nm for a period of up to 34 h. The radiation source used was a xenon lamp. A filter system (type: Suprax filter) was placed between the radiation source and the samples to be irradiated in order to simulate irradiation under realistic conditions of use of the TTS. The active ingredient content in the TTS
was then determined. It revealed that the TTS of formulation 2 which comprised an adhesive layer with UV-absorbing substance and a separating layer still comprised more than 95% of the originally employed amount of the photosensitive active ingredient after irradiation for 34 h, whereas the TTS of formulation 1 comprised only about 3% of the originally employed amount of the photosensitive active ingredient after irradiation (Fig. 1). This demonstrates that the system according to the invention displays an improved protection from the sun under realistic conditions of use. because the UV-protective. effect of the system .
according to the invention (formulation 2) was.
considerably greater than that of the comparative system (formulation 1).
Example 2 Formulation with a photosensitive active ingredient from the group of progestogens with in each case an adhesive layer and separating layer, in which the separating layer consists of polyethylene terephthalate (Hostaphan , from Mitsubishi Polyester, Wiesbaden).
The formulation has the following composition:
1. Active ingredient-containing matrix - 1.9% progestogen - 98.1% polyisobutylene-based adhesive 2. Adhesive layer 1 and 2:
- 2.5% Tinosorb S
- 9 -- 97.5% polyacrylate-based adhesive Example 3 Formulation with a photosensitive active ingredient from the group of progestogens with in each case two adhesive layers and separating layers, in which the separating layers consist of polyethylene terephthalate (Hostaphan , from Mitsubishi Polyester, Wiesbaden).
Formulation I has the following composition:
1. Active ingredient-containing matrix:
- 1.9% progestogen - 98.1% polyisobutylene-based adhesive 2. Adhesive layer 1 and 2:
- 3% Tinuvin 400 - 97% polyacrylate-based adhesive Tinuvin 400 (from Ciba, Lampertheim) is a UV absorber of the hydroxyphenyltriazine class.
Example 4 to 12 Formulation with a photosensitive active ingredient .
from the group of progestogens with in each case at least one adhesive layer and separating layer, in which the active ingredient-containing matrix is embodied in analogy to Examples 1 to 3, and the adhesive layer comprises a polyisobutylene-based adhesive and has the compositions mentioned below.
Compo- Example sition of the adhe- 4 5 6 7 8 9 10 11 12 sive layer Tinosorb''S 2 2 2 3 3 3 4 4 4 [%1 Polyiso- 98 98 98 97 97 97 96 96 96 butylene-, based adhesive [%1 Weight per 20 30 50 20 30 50 20 30 50 unit area [g/m2]
Example 13 to 21 ¨ 10 -Formulation with a photosensitive active ingredient from the group of progestogens with in each case at least one adhesive layer and separating layer, in which the active ingredient-containing matrix is embodied in analogy to Examples 1 to 3, and the adhesive layer comprises a polyacrylate-based adhesive and has the compositions mentioned below.
Compo- Example sition of the adhe- 13 14 15 16 17 18 19 20 sive layer TinosorbS 2 2 2 3 3 3 4 4 4 1%]
Poly- 98 98 98 97 97 97 96 96 96 acrylate-based adhesive 1%]
Weight per 20 30 50 20 30 50 20 30 50 unit area [g/m2]

Claims (27)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A solid transdermal therapeutic system (TTS) with a UV
absorber, said solid transdermal therapeutic system comprising a sequence of at least three layers;
wherein said at least three layers comprise a backing layer, at least one active ingredient-containing matrix, and a detachable protective film;
wherein optionally an adhesive layer and a separating layer are present between the backing layer and the at least one active ingredient-containing matrix; and wherein said UV absorber comprises at least one hydroxy-phenyltriazine compound and said UV absorber is embedded in the backing layer, in the at least one active ingredient-containing matrix, or in the adhesive layer.
2. The solid transdermal therapeutic system as defined in claim 1, wherein said at least one hydroxyphenyltriazine compound is 2,4-bis-([4-(2'-ethylhexyloxy)-2-hydroxy]phenyl)-6-(4-methoxyphenyl)-(1,3,5)-triazine.
3. The solid transdermal therapeutic system as defined in claim 1 or 2, wherein the at least one active ingredient-containing matrix has a weight per unit area of from 30 to 150 g/m2.
4. The solid transdermal therapeutic system as defined in claim 3, wherein the weight per unit area is from 50 to 120 g/m2.
5. The solid transdermal therapeutic system as defined in any one of claims 1 to 4, wherein the adhesive layer has a weight per unit area of from 5 to 50 g/m2.
6. The solid transdermal therapeutic system as defined in claim 5, wherein the weight per unit area is from 20 to 30 g/m2.
7. The solid transdermal therapeutic system, as defined in any one of claims 1 to 6, wherein said UV absorber is present in a concentration of from 0.5 to 5% (m/m) in dissolved form in the adhesive layer.
8. The solid transdermal therapeutic system as defined in claim 7, wherein said concentration of said UV absorber is from 1.0 to 4.0% (m/m).
9. The solid transdermal therapeutic system as defined in any one of claims 1 to 8, wherein the at least one active ingredient-containing matrix and the adhesive layer are self-adhesive and substantially consist of at least one polymer;
wherein said at least one polymer is polyisobutylene, polybutene, polyacrylate, polydimethyl-siloxane, styrene-isoprene block polymers or polyisoprene, or any combination thereof.
10. The solid transdermal therapeutic system as defined in any one of claims 1 to 9, wherein said separating layer has a layer thickness of from 4 to 23 µm.
11. The solid transdermal therapeutic system as defined in claim 10, wherein said layer thickness is from 4 to 10 µm.
12. The solid transdermal therapeutic system as defined in any one of claims 1 to 11, wherein said at least one active ingredient-containing matrix contains an active pharmaceutical ingredient and said separating layer is impermeable to said active pharmaceutical ingredient and impermeable to said UV absorber.
13. The solid transdermal therapeutic system as defined in any one of claims 1 to 12, wherein said separating layer consists of a barrier polymer and said barrier polymer is polyethylene terephthalate, polyacrylonitrile, polyvinyl chloride, polyvinylidene chloride, or a copolymer or co-laminate thereof.
14. The solid transdermal therapeutic system as defined in any one of claims 1 to 13, wherein said at least one active ingredient-containing matrix contains an active pharmaceutical ingredient, said backing layer is permeable to said active pharmaceutical ingredient and said backing layer consists of polypropylene, polyethylene, polyurethane, ethylene-vinyl acetate copolymer, or a multilayer composite of the foregoing polymers with one another.
15. The solid transdermal therapeutic system as defined in any one of claims 1 to 14, wherein said UV absorber is colorless or yellowish.
16. The solid transdermal therapeutic system as defined in any one of claims 1 to 15, which is transparent or slightly opaque.
17. The solid transdermal therapeutic system as defined in any one of claims 1 to 16, which further comprises an active pharmaceutical ingredient, wherein said active pharmaceutical ingredient comprises at least one hormone.
18. The solid transdermal therapeutic system as defined in claim 17, wherein said active pharmaceutical ingredient is a progestogen.
19. The solid transdermal therapeutic system as defined in claim 18, wherein said progestogen is gestodene or levonorgestrel.
20. The solid transdermal therapeutic system as defined in claim 18, consisting of a fertility controlling preparation.
21. The solid transdermal therapeutic system as defined in claim 17, wherein said active pharmaceutical ingredient comprises a progestogen and an estrogen.
22. The solid transdermal therapeutic system as defined in claim 21, consisting of a fertility controlling preparation.
23. The solid transdermal therapeutic system as defined in claim 21, wherein said progestogen is gestodene and said estrogen is ethinyl estradiol.
24. The solid transdermal therapeutic system as defined in any one of claims 1 to 16, further comprising an active pharmaceutical ingredient, and wherein a membrane controlling release of the active pharmaceutical ingredient is absent.
25. The solid transdermal therapeutic system as defined in any one of claims 1 to 16, further comprising an active pharmaceutical ingredient, wherein said active pharmaceutical ingredient comprises gestodene and ethinyl estradiol.
26. The solid transdermal therapeutic system as defined in any one of claims 1 to 25, wherein said separating layer consists of polyethylene terephthalate.
27. The solid transdermal therapeutic system as defined in any one of claims 1 to 26, wherein said backing layer is polyethylene.
CA2605112A 2005-05-02 2006-04-28 Solid transdermal therapeutic system comprising uv absorber Expired - Fee Related CA2605112C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05009579A EP1719504A1 (en) 2005-05-02 2005-05-02 Solid transdermal therapeutic system with UV-absorber
EP05009579.3 2005-05-02
PCT/EP2006/003959 WO2006117139A2 (en) 2005-05-02 2006-04-28 Solid transdermal therapeutic system comprising uv absorber

Publications (2)

Publication Number Publication Date
CA2605112A1 CA2605112A1 (en) 2006-11-09
CA2605112C true CA2605112C (en) 2013-11-05

Family

ID=34981458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2605112A Expired - Fee Related CA2605112C (en) 2005-05-02 2006-04-28 Solid transdermal therapeutic system comprising uv absorber

Country Status (26)

Country Link
EP (2) EP1719504A1 (en)
JP (2) JP5360877B2 (en)
KR (2) KR101426218B1 (en)
CN (2) CN108969507A (en)
AR (1) AR055927A1 (en)
AU (1) AU2006243442A1 (en)
BR (1) BRPI0611087A2 (en)
CA (1) CA2605112C (en)
CR (1) CR9483A (en)
CY (1) CY1115757T1 (en)
DK (1) DK1879560T3 (en)
DO (1) DOP2006000100A (en)
EA (1) EA200702344A1 (en)
ES (1) ES2523663T3 (en)
GT (1) GT200600183A (en)
IL (1) IL186945A0 (en)
MX (1) MX2007013779A (en)
NO (1) NO20076187L (en)
PE (1) PE20061414A1 (en)
PL (1) PL1879560T3 (en)
PT (1) PT1879560E (en)
SI (1) SI1879560T1 (en)
TW (1) TW200719902A (en)
UY (1) UY29511A1 (en)
WO (1) WO2006117139A2 (en)
ZA (1) ZA200710418B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1594483E (en) 2003-02-21 2006-12-29 Schering Ag Uv stable transdermal therapeutic plaster
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
HUE031326T2 (en) 2010-09-06 2017-07-28 Bayer Ip Gmbh Low-dose transdermal patches with high drug release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
EP0453396B1 (en) * 1990-03-30 1995-12-13 Ciba SC Holding AG Paint compositions
US8173592B1 (en) * 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US6924410B2 (en) * 2000-03-17 2005-08-02 Hisamitsu Pharmaceutical Co., Ltd. Ultraviolet-screening patch
EP1452173A1 (en) * 2003-02-25 2004-09-01 Schering AG UV-stable transdermal patch
PT1594483E (en) 2003-02-21 2006-12-29 Schering Ag Uv stable transdermal therapeutic plaster
EP1664128B1 (en) * 2003-09-11 2009-01-21 Ciba Holding Inc. Water based concentrated product forms of light stabilizers made by a heterophase polymerization technique

Also Published As

Publication number Publication date
PE20061414A1 (en) 2007-01-26
MX2007013779A (en) 2008-01-22
PL1879560T3 (en) 2015-02-27
GT200600183A (en) 2007-01-03
EA200702344A1 (en) 2008-12-30
EP1719504A1 (en) 2006-11-08
KR101351161B1 (en) 2014-01-14
NO20076187L (en) 2007-11-30
EP1879560A2 (en) 2008-01-23
UY29511A1 (en) 2006-08-31
TW200719902A (en) 2007-06-01
AR055927A1 (en) 2007-09-12
ES2523663T3 (en) 2014-11-28
EP1879560B1 (en) 2014-08-27
CN101171001A (en) 2008-04-30
SI1879560T1 (en) 2015-01-30
CA2605112A1 (en) 2006-11-09
BRPI0611087A2 (en) 2010-08-03
WO2006117139A3 (en) 2007-04-19
JP5360877B2 (en) 2013-12-04
DOP2006000100A (en) 2007-01-31
CR9483A (en) 2008-01-21
AU2006243442A1 (en) 2006-11-09
CY1115757T1 (en) 2017-01-25
ZA200710418B (en) 2009-08-26
KR101426218B1 (en) 2014-08-05
JP2013177451A (en) 2013-09-09
JP2008540352A (en) 2008-11-20
IL186945A0 (en) 2008-02-09
CN108969507A (en) 2018-12-11
KR20080003854A (en) 2008-01-08
DK1879560T3 (en) 2014-11-24
PT1879560E (en) 2014-11-19
WO2006117139A2 (en) 2006-11-09
KR20130099203A (en) 2013-09-05

Similar Documents

Publication Publication Date Title
US8962013B2 (en) Multi-layered transdermal system with triazine UV absorber
US9095691B2 (en) UV stable transdermal therapeutic plaster with a UV absorbing self-adhesive layer separated from the drug matrix
KR100624502B1 (en) Transdermal therapeutic systems comprising photosensitive active substances
CA2605112C (en) Solid transdermal therapeutic system comprising uv absorber
ZA200507613B (en) UV stable transdermal therapeutic plaster

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220428